The MARCH trial has found that mucoactive agents — drugs given to help critically ill patients clear mucus from their lungs — are in common use across intensive care units, yet solid proof of their benefit or safety remains limited.
A new study published by the New England Journal of Medicine has examined the use of mucoactive agents (medicines that thin or loosen mucus in the airways) in patients suffering acute respiratory failure — a condition where the lungs can no longer supply the body with enough oxygen without support. The NEJM posted findings from the MARCH trial, noting that these drugs are “widely used to enhance airway clearance despite limited evidence of their effectiveness or safety.”
That gap between common practice and hard evidence matters. Patients on ventilators in intensive care are among the most vulnerable, and decisions about which drugs to give them carry real weight.
The MARCH trial — its full findings summarised in a short video released alongside the journal post — sets out to examine whether the routine use of these agents is backed by the clinical data that should underpin it. The NEJM attributed the findings directly to the trial, though the full detail of outcomes and patient numbers are contained within the journal publication itself.
For most Kent residents, this research sits at the level of specialist hospital care rather than GP surgeries or community health. But for anyone with a family member who has been treated for serious lung conditions in an NHS critical care unit, it reflects an ongoing effort by researchers to test assumptions that have long shaped intensive care medicine.
The NHS advises anyone concerned about breathing difficulties to contact NHS 111 for guidance, or to call 999 in an emergency.
Source: @NEJM